CTR acquires preclinical toxicology company

Press release April 6th, 2021

Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT) further strengthening the CTR group with optimised toxicological support. From April 1, TKT is a fully owned subsidiary to the holding company CTR.

The activities at TKT will continue without interruption and with the same staff, in the same facilities in Södertälje, Sweden. Elinor Hahne will continue to lead the team as CEO. The company will strengthen their partnership with the other companies in the CTR group, which means shortened communications paths and easier connection between preclinic and clinic.

“We are very proud to welcome the TKT team to CTR. Their expertise in toxicology combined with the CTR group´s expertise in clinical translational research will enable an efficient seamless service to our clients in bringing new products to the market. The ultimate winners are the patients who will get access to new and improved products sooner”, says Bengt Dahlström, chairman of the board at CTR.

Elinor Hahne, CEO at TKT comments: “We are very happy to be part of the CTR group and we are looking forward to adding even more value and expertise to our clients”.

With their seven PhD toxicologists, TKT is one of the largest toxicology consultant companies in the Nordic countries. The company was founded in 2012 and has since then supported a large number of clients to successful regulatory submissions for pharmaceutical and medical device projects. All consultants have extensive experience and expertise in risk assessment of candidate drugs, inactive ingredients, impurities as well as leachables in containers and equipment.

CTR was founded in 2016 and is the holding company for an expanding group of clinical research organisations (CROs) engaged in translational research. CTR owns Clinical Trial Consultants AB, RegSmart Life Science AB, Lablytica Life Science AB and ClinSmart Sweden AB.